| 000 | 01705 a2200445 4500 | ||
|---|---|---|---|
| 005 | 20250518091851.0 | ||
| 264 | 0 | _c20210706 | |
| 008 | 202107s 0 0 eng d | ||
| 022 | _a1432-1912 | ||
| 024 | 7 |
_a10.1007/s00210-020-01853-x _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aSabet, Nima Shokouhi | |
| 245 | 0 | 0 |
_aCurcumin attenuates bevacizumab-induced toxicity via suppressing oxidative stress and preventing mitochondrial dysfunction in heart mitochondria. _h[electronic resource] |
| 260 |
_bNaunyn-Schmiedeberg's archives of pharmacology _c08 2020 |
||
| 300 |
_a1447-1457 p. _bdigital |
||
| 500 | _aPublication Type: Journal Article | ||
| 650 | 0 | 4 |
_aAngiogenesis Inhibitors _xtoxicity |
| 650 | 0 | 4 | _aAnimals |
| 650 | 0 | 4 |
_aAntioxidants _xpharmacology |
| 650 | 0 | 4 |
_aApoptosis _xdrug effects |
| 650 | 0 | 4 |
_aBevacizumab _xtoxicity |
| 650 | 0 | 4 | _aCardiotoxicity |
| 650 | 0 | 4 |
_aCurcumin _xpharmacology |
| 650 | 0 | 4 |
_aHeart Failure _xchemically induced |
| 650 | 0 | 4 |
_aLipid Peroxidation _xdrug effects |
| 650 | 0 | 4 | _aMale |
| 650 | 0 | 4 |
_aMembrane Potential, Mitochondrial _xdrug effects |
| 650 | 0 | 4 |
_aMitochondria, Heart _xdrug effects |
| 650 | 0 | 4 |
_aMitochondrial Swelling _xdrug effects |
| 650 | 0 | 4 |
_aMyocytes, Cardiac _xdrug effects |
| 650 | 0 | 4 |
_aOxidative Stress _xdrug effects |
| 650 | 0 | 4 | _aRats, Wistar |
| 650 | 0 | 4 |
_aReactive Oxygen Species _xmetabolism |
| 700 | 1 | _aAtashbar, Saman | |
| 700 | 1 | _aKhanlou, Elham Mohammad | |
| 700 | 1 | _aKahrizi, Farzad | |
| 700 | 1 | _aSalimi, Ahmad | |
| 773 | 0 |
_tNaunyn-Schmiedeberg's archives of pharmacology _gvol. 393 _gno. 8 _gp. 1447-1457 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1007/s00210-020-01853-x _zAvailable from publisher's website |
| 999 |
_c30742473 _d30742473 |
||